Opthea LTD (OPTEY) SEC Filings — 2025
25 SEC filings for Opthea LTD (OPTEY) in 2025.
Filings
- Opthea Ltd Files 6-K Report — 6-K · Nov 20, 2025
- Opthea LTD 6-K Filing — 6-K · Nov 12, 2025
- Opthea LTD 6-K Filing — 6-K · Oct 31, 2025
- Opthea Ltd Files 6-K, Incorporates by Reference — 6-K · Oct 30, 2025
- Opthea Appoints New Company Secretary — 6-K · Oct 27, 2025
- Opthea Ltd Files Notice of Annual General Meeting — 6-K · Oct 10, 2025
- Opthea Secures A$10.8M R&D Tax Incentive — 6-K · Oct 6, 2025
- Opthea Scraps Flagship Drug, Pays $20M to Exit Funding Deal — 20-F · Sep 15, 2025
- Opthea Ltd Files Preliminary Final Report — 6-K · Aug 29, 2025
- Opthea Ltd Files 6-K with Corporate Update — 6-K · Aug 20, 2025
- Opthea Ltd. Files August Corporate Update (6-K) — 6-K · Aug 19, 2025
- Opthea Ltd Files 6-K Corporate Update — 6-K · Jun 2, 2025
- Opthea Ltd Files 6-K Corporate Update — 6-K · Apr 10, 2025
- Opthea Discontinues Wet AMD Trials — 6-K · Mar 31, 2025
- Opthea's Wet AMD Trial Meets Primary Endpoint — 6-K · Mar 24, 2025
- Opthea Publishes Phase 2b Wet AMD Trial Results — 6-K · Mar 3, 2025
- Opthea Ltd Files Half Year Results and Business Updates — 6-K · Feb 28, 2025
- Opthea Completes Key Drug Product PPQ Campaign — 6-K · Feb 26, 2025
- Opthea Completes Final Patient Visit for COAST Trial — 6-K · Feb 18, 2025
- Opthea to Present at Oppenheimer Healthcare Conference — 6-K · Feb 7, 2025
- Opthea Presents Wet AMD Trial Data at Macula Society Meeting — 6-K · Feb 6, 2025
- Opthea Ltd Files 6-K, Includes Investor Day Press Release — 6-K · Jan 28, 2025
- Opthea Ltd Updates Corporate Presentation — 6-K · Jan 13, 2025
- Opthea Ltd to Host Investor Days in NY and Australia — 6-K · Jan 8, 2025
- Opthea's DME Trial Data Published in NEJM — 6-K · Jan 7, 2025